OSTEOPONTIN-REGULATED CHANGES IN THE MAST CELL POPULATION ASSOCIATED WITH BREAST CANCER

Authors

  • О. MUSHII R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • А. PAVLOVA R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • V. BAZAS Kyiv City Clinical Oncology Center, Kyiv, Ukraine
  • T. ZADVORNYI R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • N. LUKIANOVA R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2024.03.209

Keywords:

breast cancer, mast cells, osteopontin, prognosis

Abstract

Background. The development of breast cancer (BCa) is largely determined by the characteristics of the tumor microenvironment (ТМЕ), which undergoes significant changes during the progression of the disease. Mast cells (MCs) are among the least studied components of the TME. The aim of the work was to investigate the relationship between the density of infiltration and the functional activity of MCs with indicators of osteopontin (OP) expression in BCa tissue. Materials and Methods. The study was conducted on the postoperative material of 15 patients with fibroadenoma and 78 patients with stage I—II BCa. MCs in the tissue of benign and malignant breast tumors were detected by a histochemical method using toluidine blue. The functional activity of MCs was calculated by the degranulation index. The OP expression in tumor tissue was assessed by the immunohistochemical method. Results. The density of MCs infiltration and their functional activity are associated with such indicators of BCa malignancy as tumor size, lymph node involvement, tumor grade, molecular subtype, proliferative activity, and PR- and HER2/neu-expression status. A high expression of OP in the stromal component of BCa is associated with the growth of the tumoral MCs population, metastatic lesions in regional lymph nodes, and a low differentiation grade of the tumors. In addition, OP is involved in the regulation of MCs in the tissue of the luminal B and basal molecular BCa subtypes. The level of OP expression in the parenchymal component of BCa is associated with the number of infiltrated MCs in the presence of metastatic lesions of regional lymph nodes. Conclusions. The identified relationship of OP expression level with the topology and functional activity of MCs in BCa tissue, depending on the clinical status of patients, indicates the prospects for their use in predicting the aggressiveness of the tumor process.

References

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229­263. https://doi.org/10.3322/caac.21834

Chekhun V, Martynyuk О, Lukianova Y, et al. Features of breast cancer in patients of young age: search for diagnosis optimization and personalized treatment. Exp Oncol. 2023;45(2):139­150. doi: 10.15407/exp­oncology.2023.02.139

American Cancer Society: Atlanta. Breast Cancer Facts and Figures 2017–2018; GA, USA, 2017.

Yang J, Bahcecioglu G, Zorlutuna P. The Extracellular matrix and vesicles modulate the breast tumor microenviron­ ment. Bioengineering (Basel). 2020;7(4):124. https://doi.org/10.3390/bioengineering7040124

Tan Z, Kan C, Sun M, et al. Mapping breast cancer microenvironment through single­cell omics. Front Immunol.

;13:868813. https://doi.org/10.3389/fimmu.2022.868813

Ribatti D, Annese T, Tamma R. Controversial role of mast cells in breast cancer tumor progression and angiogenesis.

Clin Breast Cancer. 2021;21(6):486­491. https://doi.org/10.1016/j.clbc.2021.08.010

Maciel TT, Moura IC, Hermine O. The role of mast cells in cancers. F1000Prime Rep. 2015;7:09. https://doi. org/10.12703/P7­09

Sacks D, Baxter B, Campbell В, et al. Multisociety Consensus Quality Improvement Revised Consensus State­ ment for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018;13(6):612­632. https://doi. org/10.1177/1747493018778713

Dyduch G, Kaczmarczyk K, Okoń K. Mast cells and cancer: enemies or allies? Pol J Pathol. 2012;63(1):1­7.

Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693­704. https://doi.org/10.1038/nm.2755

Eissmann MF, Buchert M, Ernst M. IL33 and mast cells – the key regulators of immune responses in gastrointestinal cancers? Front Immunol. 2020;11:1389. https://doi.org/10.3389/fimmu.2020.01389

Tiwari A, Trivedi R, Lin SY. Tumor microenvironment: barrier or opportunity towards effective cancer therapy.

J Biomed Sci. 2022;29(1):83. https://doi.org/10.1186/s12929­022­00866­3

Zadvornyi T, Lukianova N, Borikun T, et al. Mast cells as a tumor microenvironment factor associated with the ag­ gressiveness of prostate cancer. Neoplasma. 2022;69(6):1490­1498. https://doi.org/10.4149/neo_2022_221014N1020

Lamort AS, Giopanou I, Psallidas I, et al. Osteopontin as a link between inflammation and cancer: the thorax in the spotlight. Cells. 2019;8(8):815. https://doi.org/10.3390/cells8080815

Linder DP, Poberiĭ IA, Rozkin MIa, et al. Morphometric analysis of a mast cell population. Arkh Patol. 1980;42(6):60­64.

McClelland RA, Wilson D, Leake R, et al. A multicentre study into the reliability of steroid receptor immunocy­ tochemical assay quantification. British Quality Control Group. Eur J Cancer. 1991;27(6):711­715. https://doi. org/10.1016/0277­5379(91)90171­9

Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue ­ a review. Diagn Pathol. 2014;9:221. https://doi.org/10.1186/s13000­014­0221­9

Seyed Jafari SM, Hunger RE. IHC Optical density score: a new practical method for quantitative immunohisto­ chemistry image analysis. Appl Immunohistochem Mol Morphol. 2017;25(1):e12­e13. https://doi.org/10.1097/ PAI.0000000000000370

Chekhun V, Pavlova A, Zadvornyi T, et al. Expression of SPP1 and SPARC genes in tumor tissue of patients with breast cancer. Exp Oncol. 2024;46(1):13­21. https://doi.org/10.15407/exp­oncology.2024.01.013

Kashiwase Y, Morioka J, Inamura H, et al. Quantitative analysis of mast cells in benign and malignant breast le­ sions. Immunohistochemical study on formalin­fixed, paraffin­embedded tissues. Int Arch Allergy Immunol. 2004;134(3):199­205. https://doi.org/10.1159/000078766

Löfdahl B, Ahlin C, Holmqvist M, et al. Inflammatory cells in node­negative breast cancer. Acta Oncol. 2012;51(5):680­ 686. https://doi.org/10.3109/0284186X.2011.652737

Fakhrjou A, Naghavi­Behzad M, Montazeri V, et al. The relationship between histologic grades of invasive carcinoma of breast ducts and mast cell infiltration [published correction appears in South Asian J Cancer. 2016;5(3):166. doi: 10.4103/2278­330X.187594]. South Asian J Cancer. 2016;5(1):5­7. https://doi.org/10.4103/2278­330X.179699

Glajcar A, Szpor J, Pacek A, et al. The relationship between breast cancer molecular subtypes and mast cell popula­ tions in tumor microenvironment. Virchows Arch. 2017;470(5):505­515. https://doi.org/10.1007/s00428­017­2103­5

Pyla RD, Potekar RM, Patil VS, et al. Quantitative mast cell analysis and hormone receptor study (ER, PR and HER2/neu) in invasive carcinoma of breast. Indian J Pathol Microbiol. 2020;63(2):200­204. https://doi.org/10.4103/IJPM.IJPM_155_19

Xiang M, Gu Y, Zhao F, et al. Mast cell tryptase promotes breast cancer migration and invasion. Oncol Rep.

;23(3):615­619. https://doi.org/10.3892/or_00000676

Amini RM, Aaltonen K, Nevanlinna H, et al. Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer.

;7:165. https://doi.org/10.1186/1471­2407­7­165

Keser SH, Kandemir NO, Ece D, et al. Relationship of mast cell density with lymphangiogenesis and prognostic pa­ rameters in breast carcinoma. Kaohsiung J Med Sci. 2017;33(4):171­180. https://doi.org/10.1016/j.kjms.2017.01.005

Zadvornyi T, Lukianova N, Borikun T, et al. Mast cells as a tumor microenvironment factor associated with the ag­ gressiveness of prostate cancer. Neoplasma. 2022;69(6):1490­1498. https://doi.org/10.4149/neo_2022_221014N1020

Lukianova N, Zadvornyi T, Kashuba E, et al. Expression of markers of bone tissue remodeling in breast cancer and prostate cancer cells in vitro. Exp Oncol. 2022;44(1):39­46. https://doi.org/10.32471/exp­oncology.2312­8852.vol­44­ no­1.17354

Baiula M, Spampinato S, Gentilucci L, et al. Novel ligands targeting α4β1 integrin: therapeutic applications and per­ spectives. Front Chem. 2019; 7:489. https://doi.org/10.3389/fchem.2019.00489

Abonia JP, Hallgren J, Jones T, et al. Alpha­4 integrins and VCAM­1, but not MAdCAM­1, are essential for re­ cruitment of mast cell progenitors to the inflamed lung. Blood. 2006;108(5):1588­1594. https://doi.org/10.1182/ blood­2005­12­012781

Nagasaka A, Matsue H, Matsushima H, et al. Osteopontin is produced by mast cells and affects IgE­mediated de­ granulation and migration of mast cells. Eur J Immunol. 2008;38(2):489­499. https://doi.org/10.1002/eji.200737057

Downloads

Published

19.12.2024

How to Cite

MUSHII О., PAVLOVA А., BAZAS, V., ZADVORNYI, T., & LUKIANOVA, N. (2024). OSTEOPONTIN-REGULATED CHANGES IN THE MAST CELL POPULATION ASSOCIATED WITH BREAST CANCER. Experimental Oncology, 46(3), 209–220. https://doi.org/10.15407/exp-oncology.2024.03.209

Issue

Section

Original contributions

Most read articles by the same author(s)

1 2 > >>